Proteintech, HebeCell to develop cancer immunotherapies

By The Science Advisory Board staff writers

November 12, 2020 -- Proteintech and HebeCell have announced a partnership to develop nanobody-based chimeric antigen receptors (nCARs) for cancer cellular immunotherapy use.

The nCAR technology will be used to develop induced pluripotent stem cells (iPSCs) -derived natural killer cells, according to the firms. Proteintech recently acquired ChromoTek, which augmented its nanobody development resources, while HebeCell holds intellectual property regarding natural killer cells.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.